Arzneimittelforschung 2012; 62(12): 595-598
DOI: 10.1055/s-0032-1327611
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetics of Ginkgolide B Injection in Beagle Dogs

H. Song1, F. Bu1, C. Wei1, G. Yuan1, X. Liu1, B. Wang1, R. Guo1
  • 1Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, P.R. of China
Further Information

Publication History

received 23 February 2012

accepted 18 September 2012

Publication Date:
23 October 2012 (eFirst)



A liquid chromatography-mass spectrometry method was developed, validated, and applied to the pharmacokinetic study with doses of 0.68, 2.73 and 10.92 mg/kg of ginkgolide B in beagle dogs after intravenous infusion.


An aliquot of blood samples were ­collected, separated and quantitatively analyzed by liquid chromatography-mass spectrometry method with mobile phase of acetonitrile-0.02% ammonia solution (33:67, v/v) at a flow rate of 0.8 mL/min on the UltimateTM XB-C18 column (5 μm, 4.6×150 mm).


The method was sensitive, accurate and convenient, and can be used for the determination of ginkgolide B in beagle dogs. The Cmax and AUC0-∞ of GB increased with dose escalation, but ANOVA analyses showed that no significant difference was observed in other pharmacokinetic parameters between different doses.


An LC/MS method was developed with good sensitivity, reproducibility and specificity. In the pharmacokinetic study of GB in beagle dogs, linear pharmacokinetics was found at doses from 0.62 to 10.92 mg/kg after a single-dose intravenous infusion. Gender differences were not observed in the pharmacokinetics of GB.